1. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. Issue 1 (December 2017) Authors: Shah, Parth; Glueck, Charles; Goldenberg, Naila; Min, Sarah; Mahida, Chris; Schlam, Ilana; Rothschild, Matan; Huda, Ali; Wang, Ping Journal: Lipids in health and disease Issue: Volume 16:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗